ddATP trisodium
(Synonyms: 2',3'-Dideoxyadenosine 5'-triphosphate trisodium) 目录号 : GC68952ddATP (2',3'-Dideoxyadenosine 5'-triphosphate) trisodium，一种 2',3'-二脱氧肌苷的活性代谢物，是 DNA 聚合酶 (DNA polymerase) 的链延长抑制剂。ddATP trisodium 可用于 Sanger 法进行 DNA 测序，以及病毒感染相关的研究。
Cas No.:72029-21-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
ddATP (2',3'-Dideoxyadenosine 5'-triphosphate) trisodium, an active metabolite of 2',3'-dideoxyinosine, is a chain-elongating inhibitor of DNA polymerase. ddATP trisodium can be used for Sanger method for DNA sequencing and research of virus Suppressed the mtDNA replication without fully suppressed the nuclear DNA replication.
[1]. van der Vliet PC, et al. Role of DNA polymerase gamma in adenovirus DNA replication. Mechanism of inhibition by 2',3'-dideoxynucleoside 5'-triphosphates. Biochemistry. 1981 Apr 28;20(9):2628-32.
[2]. Xu Lan, et al. Simultaneous determination of 2 ,3 -dideoxyinosine and the active metabolite, 2 ,3 -dideoxyadenosine-5 -triphosphate in human peripheral-blood mononuclear cell by HPLC-MS/MS and the application to cell pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:337-42.
[3]. Jun-Yu Ma, et al. Double-strand breaks induce short-scale DNA replication and damage amplification in the fully grown mouse oocytes. Genetics. 2021 Jun 24;218(2):iyab054.
[4]. C M Perry, et al. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs. 1996 Dec;52(6):928-62.
[5]. Hao Z, et al. Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol. 1988 Oct;34(4):431-5.
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.848 mL | 9.2399 mL | 18.4798 mL |
| 5 mM | 0.3696 mL | 1.848 mL | 3.696 mL |
| 10 mM | 0.1848 mL | 0.924 mL | 1.848 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。